Quest Diagnostics projects $11.95B-$12.05B 2026 revenue while raising EPS outlook again

The revenue outlook for 2026 has been raised to $11.95B-$12.05B, and the EPS forecast has been upgraded once again, indicating a clear performance-driving capability. This is expected to serve as a signal reaffirming the growth sustainability of DGX's core diagnostics business. In particular, the upward revision of the EPS forecast suggests the possibility of simultaneously achieving cost efficiency and increased demand, which is likely to lead to an improvement in ROE.

With an RSI of 40.9, it is not in the overbought range, but since the MA_align is bullish and trading volume has surged, there is a high likelihood that the upward trend will continue. There is potential for further gains if the resistance level is breached.

The upward revision of the annual revenue forecast (from $11.95B to $12.05B) and the upward revision of the EPS forecast are key drivers strengthening DGX's performance growth story. In particular, the upward revision of the EPS forecast indicates that a balance between cost management and increased demand is being maintained, which could serve as a basis for not only a short-term performance rebound but also a medium- to long-term valuation reassessment. Additionally, the volume_ratio_vs_20d_avg at 2.10 times reflects the market's strong response to the positive performance news.